Seyed Negar, Zahedifard Farnaz, Habibzadeh Sima, Yousefi Roya, Lajevardi Mahya Sadat, Gholami Elham, Rafati Sima
Immunotherapy and Leishmania Vaccine Research Department, Pasteur Institute of Iran, Tehran 1316943551, Iran.
Vaccines (Basel). 2022 Oct 13;10(10):1710. doi: 10.3390/vaccines10101710.
DNA vaccines with their extraordinary properties are the best choice as vectors for subunit vaccines but are not in compliance with safety regulations, mainly because of the antibiotic resistance genes on their backbone. New generations of plasmids with minimum bacterial backbones are now developed as promising alternatives to pass the safety rules and be replaced for conventional plasmids. Here we have compared the nanoplasmid (with RNA-out selection system and professional HTLV-1 containing promoter) and the conventionally used pcDNA plasmid, as regards the transfection efficiency. The EGFP gene was cloned in both pcDNA-3.1 and NTC9385R-MSC and transfected into COS-7 cells for expression evaluation by flow cytometry. Meanwhile, qPCR was used to analyze the EGFP mRNA copy numbers. It was concluded that the nanoplasmid, with its extraordinary properties, can be a tempting alternative to conventional pcDNA in equal or equimolar concentrations for vaccine design. These promising results can put DNA vaccines back into focus, especially regarding diseases controlled by robust cellular immune responses.
具有非凡特性的DNA疫苗是亚单位疫苗载体的最佳选择,但不符合安全规定,主要是因为其骨架上的抗生素抗性基因。现在开发出具有最小细菌骨架的新一代质粒,作为有望通过安全规则并取代传统质粒的替代品。在这里,我们比较了纳米质粒(具有RNA-out筛选系统和含专业HTLV-1启动子)和传统使用的pcDNA质粒在转染效率方面的差异。将EGFP基因克隆到pcDNA-3.1和NTC9385R-MSC中,并转染到COS-7细胞中,通过流式细胞术评估其表达情况。同时,使用qPCR分析EGFP mRNA拷贝数。结果表明,纳米质粒具有非凡特性,在等浓度或等摩尔浓度下,对于疫苗设计而言,它可能是传统pcDNA颇具吸引力的替代品。这些有前景的结果能够使DNA疫苗重新成为焦点,尤其是对于那些由强大的细胞免疫反应控制的疾病。